Imagine a world where anyone who needs a bone marrow transplant can get one — on demand. No more desperate donor searches or deadly delays. Kevin Caldwell, Co-Founder & CEO, Ossium Health.
Bone marrow transplants have always depended on finding the right donor at the right time. But what if bone marrow could be stored, shipped, and used on demand—just like a drug? That’s exactly what Ossium Health is now showing in human clinical data.
Kevin Caldwell is the Co-Founder, CEO, and President of Ossium Health (https://ossiumhealth.com/), a clinical-stage bioengineering company pioneering off-the-shelf, cryopreserved bone marrow therapies derived from deceased organ donors.
Under Kevin’s leadership, Ossium has developed a novel platform designed to solve one of the most persistent challenges in transplantation medicine: timely access to compatible bone marrow for patients with life-threatening hematologic malignancies such as Acute Myeloid Leukemia. The company’s approach enables on-demand delivery of viable marrow cells, bypassing the logistical and biological constraints of traditional donor matching and scheduling.
Since its founding, Kevin has scaled Ossium from an early-stage startup into a clinical-stage company with a robust network of over 50 strategic partnerships across supply, clinical development, and commercial channels. He has led multiple financings and secured a landmark contract with the Biomedical Advanced Research and Development Authority, validating Ossium’s relevance to national health preparedness and biomanufacturing resilience.







